Astex and Cardiff University Medicines Discovery Institute Announce New Drug Discovery Collaboration on Neurodegenerative Diseases
Cambridge and Cardiff, UK, 13 February 2023, Astex Pharmaceuticals (UK) (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system and The Medicines Discovery Institute, Cardiff University (“MDI”) announced today that they have entered into a multi-year, multimillion pound drug discovery research collaboration, aimed to identify new drugs to treat…
February 11th marks International Day of Women and Girls in science, the purpose of which is to promote the ‘full and equal access and participation of females in STEM’.
According to United Nations, “Gender equality, besides being a fundamental human right, is essential to achieve peaceful societies, with full human potential and sustainable development.”
Gender diversity in science can have many advantages, yet organisations continue to lag behind in female representation. But the truth is, we need more girls and women in science, so we must explore how these gender differences can be better…
NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
● Gilles Ouvry Ph.D, appointed to newly created position of VP of Chemistry, based in Stevenage, UK
● Joins from Evotec, UK and brings 20 years of international medicinal chemistry experience including at Galderma, AstraZeneca and SCYNEXIS
● Will be responsible for developing NRG’s pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore as treatments for Parkinson's…
The next SysMIC Module 1 Course will start on Monday 24th April 2023.
The SysMIC course is run online from University College London and enables bioscience researchers to access an extended programme of training in coding, modelling and data analysis techniques.
Participants will become confident in using the Python, R and MATLAB platforms, developing interdisciplinary skills that will make them more effective researchers with the confidence to develop and apply computational techniques in modelling and data analysis to their own work.
Why SysMIC
Our materials were designed by bioscientists…
Oversubscribed round led by Foresite CapitalFunding will enable development of DNA synthesis chip technology to commercial scale
Cambridge, UK 07 February 2023– EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has completed a USD $24 million financing round, extending its total series B funding to over USD $54 million (circa GB £44 million). This fundraise was led by existing investor Foresite Capital, with Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence also…
We are today pleased to share the annual trading update for Bruntwood SciTech for 2022, which includes an overview of the £91m capital investment we confirmed last year. Very positively, it is our best performing year since forming in a partnership between Bruntwood and Legal & General in 2018, and we have and will continue to display an unwavering commitment to further cement the UK's position as an R&D powerhouse this year and beyond.
View the results via the links below.
Twitter: https://twitter.com/BW_SciTech/status/1622505938354688000
LinkedIn: https://www.linkedin.com/…
Apply for the Primer Fund
Are you developing a solution to accelerate the diagnosis of MND? We're seeking proposals for funding in the areas of point of care diagnostic markers, digital markers of early symptoms and algorithmic approaches applied to pt data to detect changes indicative of MND. Proposals welcome from academia and industry. Deadline 20th Feb.
York, UK (January 31, 2023) – Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces a new partnership with BaseCure Therapeutics for the development of Optimer-targeted gene therapies. The ability to precisely target gene therapies, like siRNA-based therapeutics, to specific cells and tissues using Optimers offers exciting new opportunities for the field of gene therapy.
BaseCure Therapeutics is a pre-clinical stage biotech company dedicated to the discovery and development of innovative siRNA-based…